Transcriptomic Evidence Identifies Two TMBIM Subgroups with Opposing Prognostic Associations in Glioma

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Genomics

Background:

• Gliomas, particularly glioblastoma (GB), are aggressive brain tumors with poor prognoses.
• Intracellular calcium (Ca2+) signaling dysregulation is crucial in glioma progression.
• The role of the transmembrane BAX inhibitor motif-containing (TMBIM) protein family in glioma is not fully understood.

Purpose of the Study:

• To investigate the expression patterns and clinical significance of the TMBIM protein family in glioma.
• To identify TMBIM-associated molecular pathways and their functional implications in glioma progression.
• To explore the potential of TMBIM proteins as prognostic markers and therapeutic targets in glioma.

Main Methods:

• Analysis of gene expression and clinical data from TCGA, CGGA, and Rembrandt patient cohorts.
• Correlation analyses to identify TMBIM-associated gene networks.
• Functional enrichment analyses (GO, KEGG) to characterize biological processes and molecular functions.

Main Results:

• TMBIM family members exhibited distinct expression patterns and clinical associations in glioma.
• TMBIM1, TMBIM4, and TMBIM6 were upregulated and associated with poor patient survival.
• TMBIM2, TMBIM3, and TMBIM5 were downregulated and linked to increased patient survival.
• Upregulated TMBIMs (1, 4, 6) were associated with membrane trafficking and metabolic adaptation.
• Downregulated TMBIMs (2, 3, 5) were linked to cell cycle regulation and chromosomal instability.

Conclusions:

• The TMBIM protein family displays functional divergence in glioma, with distinct subgroups correlating with patient outcomes.
• TMBIM proteins represent potential prognostic biomarkers for glioma.
• Targeting specific TMBIM subgroups may offer novel therapeutic strategies for glioma treatment.